Results 241 to 250 of about 66,268 (303)

Advancing IBD Management: A Literature Review on the Role of Non‐Invasive Blood‐Based Biomarkers in Predicting and Assessing Pharmacodynamic Response to Treatment

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Reliable biomarkers that enable noninvasive, longitudinal assessment of disease activity and therapeutic response remain a major unmet need in inflammatory bowel disease (IBD). While colonic biopsies are the gold standard for evaluating mucosal inflammation, their invasive nature and limited spatial and temporal resolution constrain their ...
Mohamed Hassanein, Li Xi, Rathi D. Ryan, Zhan (Harold) Ye, Nessy Tania, Yamato Sano, Joshua Varghese, Diogo Branquinho, Anna Sapone   +8 more
wiley   +1 more source

Association of Dipeptidyl Peptidase-4 Inhibitors with Glaucoma Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study. [PDF]

Ophthalmol Sci
Lu YA, Tien PT, Cheng YD, Hsieh YW, Cho DY, Tsai SF, Weng CH, Lin HJ, Lin HJ, Wang IJ, Chou CC.   +10 more
europepmc   +1 more source

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, Volume 43, Issue 5, May 2026.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease. [PDF]

Gut Liver
Ko Y, Hur MH, Park Y, Park J, Shin H, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.   +10 more
europepmc   +1 more source

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3692-3702, May 2026.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich, Morten Frost Nielsen, Nicola Napoli, Andrea M. Burden   +3 more
wiley   +1 more source

Dipeptidyl Peptidase 4 (DPP4) Exacerbates Osteoarthritis Progression in an Enzyme-Independent Manner. [PDF]

Adv Sci (Weinh)
Li X, Zhang Z, Jiang W, Ju Y, Guo W, Huang Z.   +5 more
europepmc   +1 more source

Dipeptidyl peptidase-4 inhibitor approaches.

Journal of diabetes, 2019
openaire   +1 more source

Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3703-3715, May 2026.
Abstract Aims Despite the established efficacy of tirzepatide in randomised controlled trials, real‐world effectiveness data in Japanese patients remain limited. This study evaluated the real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks.
Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa   +3 more
wiley   +1 more source

Dipeptidyl peptidase-4 deficiency prevents chronic stress-induced cardiac remodeling and dysfunction in mice. [PDF]

FASEB J
Jiang Z, Zhao L, Xin M, Wan Y, Xu S, Yue X, Jin X, Cui R, Li Y, Kim W, Wu H, Cheng XW.   +11 more
europepmc   +1 more source

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3807-3818, May 2026.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye, Jonathan Goldney, Thomas Yates, Francesco Zaccardi, Kamlesh Khunti, Elina Akalestou, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis   +8 more
wiley   +1 more source